SCHEMBL4255166

SCHEMBL4255166

CC(C(=O)O)c1ccc(C(=O)c2ccc(O)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.58
MAPT P10636 4/20 0.58
HPGD P15428 3/20 0.58
ESR1 P03372 2/20 0.58
HTT P42858 2/20 0.58
ESR2 Q92731 1/20 0.58
PKM P14618 1/20 0.58
PTGS2 P35354 9/20 0.57
PTGS1 P23219 8/20 0.57
CYP2C9 P11712 5/20 0.57
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 2/20 0.57
RXFP1 Q9HBX9 1/20 0.57
SRD5A2 P31213 1/20 0.55
CXCR1 P25024 4/20 0.54
CXCR2 P25025 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
CYP3A4 P08684 2/20 0.54
PMP22 Q01453 2/20 0.54
SLC22A6 Q4U2R8 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288003 0.90 PTGS2 (0.63) LMNAHPGDESR1ESR2PTGS2
SCHEMBL892055 0.90 PTGS2 (0.63) LMNAHPGDESR1ESR2PTGS2
SCHEMBL1345582 0.90 PTGS2 (0.63) LMNAHPGDESR1ESR2PTGS2
Hydrochloric Acid SCHEMBL28716582 0.88 PTGS2 (0.61) LMNAHPGDESR1ESR2PTGS2
SCHEMBL9232479 0.88 PTGS2 (0.61) LMNAHPGDESR1ESR2PTGS2
SCHEMBL9232475 0.88 PTGS2 (0.61) LMNAHPGDESR1ESR2PTGS2
SCHEMBL9234136 0.88 PTGS2 (0.61) LMNAHPGDESR1ESR2PTGS2
SCHEMBL7704968 0.86 PTGS2 (0.71) LMNAMAPTHPGDESR1PTGS2
SCHEMBL5313395 0.86 PTGS2 (0.71) LMNAMAPTHPGDESR1PTGS2
SCHEMBL1678786 0.84 PTGS2 (0.74) LMNAESR1PTGS2PTGS1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569601-B2 Cycloalkylidene compounds as modulators of estrogen receptor SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
US-20070213348-A1 Chemical Compounds BRITTON JONATHAN E 2007-09-13 US disclosed
EP-0923527-A1 A PROCESS FOR THE PREPARATION OF 2-(3-BENZOYL-PHENYL)-PROPIONIC ACID STARTING FROM ARYL-OLEFINS Dompé S.P.A. (IT) 1999-06-23 EP disclosed
WO-1998005623-A1 A PROCESS FOR THE PREPARATION OF 2-ARYL-PROPIONIC AND 2-ARYL-ACETIC ACIDS STARTING FROM ARYL-OLEFINS DOMPE' S.P.A. (IT) 1998-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213348-A1 Chemical Compounds GPER1, ESR2, ESR1 LMNA 4504/4885MAPT 3451/4885HPGD 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.